Oppenheimer Analysts Give Heron Therapeutics (HRTX) a $34.00 Price Target

Lloyd Doyle
May 15, 2018

The performance of the stock over the past seven days has dropped by -3.17%, over the past one-month price index is 12.73% while over the last three months is +50.49%.

Heron Therapeutics traded up $1.00, reaching $30.75, during midday trading on Friday, MarketBeat.com reports. Heron Therapeutics had 17 analyst reports since December 6, 2017 according to SRatingsIntel. Oppenheimer set a $34.00 target price on Heron Therapeutics and gave the company a "buy" rating in a research report on Thursday. Therefore 100% are positive. Heron Therapeutics has a fifty-two week low of $28.60 and a fifty-two week high of $31.40. $41.57's average target is 35.19% above currents $30.75 stock price. Finally, American International Group Inc. increased its holdings in shares of Heron Therapeutics by 13.4% in the 1st quarter. The rating was maintained by Cowen & Co with "Buy" on Tuesday, January 16. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. They set an "outperform" rating and a $56.00 target price on the stock. Cowen restated a "buy" rating and issued a $48.00 target price on shares of Heron Therapeutics in a research note on Tuesday, May 8th. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. The firm has "Buy" rating by Bank of America given on Wednesday, September 2.

In related news, CEO Barry D. Quart sold 100,000 shares of the firm's stock in a transaction that occurred on Monday, March 19th. The rating was maintained by Cantor Fitzgerald on Sunday, April 22 with "Buy". The value there would make it reasonable for the investors to decide the dimensions of Heron Therapeutics, Inc. not at all like the standard sales or statistics of their aggregate resources.


Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Thursday, May 10th. Heron Therapeutics had a negative net margin of 641.87% and a negative return on equity of 230.70%. The rating was maintained by Northland Capital on Monday, March 26 with "Buy". Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics. The company has a market capitalization of $2.20 billion, a P/E ratio of 8.00 and a beta of 1.88. It offers SUSTOL extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. If the answer is greater than 1, it indicates that the price of the stock is in gaining momentum. The biotechnology company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.87) by $0.06. BidaskClub upgraded shares of Heron Therapeutics from a hold rating to a buy rating in a report on Saturday, January 20th. The lowest target is $70.0 while the high is $70.0. The stock's average target of $70 is -20.86% below today's ($88.45) share price.

Hill-Rom Holdings, Inc. operates as a medical technology firm worldwide. The company has market cap of $5.86 billion. Ellington Management Group LLC purchased a new stake in shares of Heron Therapeutics in the fourth quarter valued at about $195,000. Streetinsider.com's article titled: "Hill-Rom Holdings (HRC) & IMRIS Report Commercial Launch of New Magnetic Resonance Neurosurgical Table" and published on May 01, 2018 is yet another important article.

Wells Fargo & Company MN now owns 130,374 shares of the biotechnology company's stock valued at $2,106,000 after buying an additional 87,212 shares in the last quarter.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER